AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa.

Abstract

Base editing technology is an ideal solution for treating pathogenic single-nucleotide variations (SNVs). No gene editing therapy has yet been approved for eye diseases, such as retinitis pigmentosa (RP). Here, we show, in the rd10 mouse model, which carries an SNV identified as an RP-causing mutation in human patients, that subretinal delivery of an optimized dual adeno-associated virus system containing the adenine base editor corrects the pathogenic SNV in the neuroretina with up to 49% efficiency. Light microscopy showed that a thick and robust outer nuclear layer (photoreceptors) was preserved in the treated area compared with the thin, degenerated outer nuclear layer without treatment. Substantial electroretinogram signals were detected in treated rd10 eyes, whereas control treated eyes showed minimal signals. The water maze experiment showed that the treatment substantially improved vision-guided behavior. Together, we construct and validate a translational therapeutic solution for the treatment of RP in humans. Our findings might accelerate the development of base-editing based gene therapies.

• Authors: Yidong Wu, Xiaoling Wan, Dongdong Zhao, Xuxu Chen, Yujie Wang, Xinxin Tang, Ju Li, Siwei Li, Xiaodong Sun, Changhao Bi, Xueli Zhang
• Journal: Nature communications (Nat Commun) Vol. 14 Issue 1 Pg. 4923 (08 15 2023) ISSN: 2041-1723 [Electronic] England
• PMID: 37582961 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2023. Springer Nature Limited.

Topics

• Mice
• Animals
• Humans
• Retinitis Pigmentosa (genetics, therapy)
• Retina (pathology)
• Electroretinography
• Photoreceptor Cells
• Disease Models, Animal
• Phenotype